Advertisement
Advertisement
Coronavirus pandemic
Get more with myNEWS
A personalised news feed of stories that matter to you
Learn more
A health worker checks a syringe before administering a vaccine in India. Photo: AP Photo

Coronavirus: WHO suspends UN supply of Indian vaccine after inspection of maker’s facilities

  • Production of Covaxin by Bharat Biotech is being put on hold to allow the company to upgrade facilities and address deficiencies
  • The WHO said the vaccine is effective and no safety concerns exist, but the suspension of production for export will result in the interruption of supply

The World Health Organization said on Saturday it has suspended supply through United Nations agencies of the Covid-19 vaccine Covaxin, produced by India’s Bharat Biotech, to allow the manufacturer to upgrade facilities and address deficiencies found in an inspection.

The WHO asked countries that have received the vaccine to take appropriate actions, according to the statement, but did not specify what the appropriate actions would be.

India’s biotechnology company Bharat Biotech will suspend production of it Covaxin vaccination following a report. Photo: Reuters

The WHO said the vaccine is effective and no safety concerns exist, but the suspension of production for export will result in the interruption of Covaxin supply.

It said the suspension is in response to the outcomes of WHO post emergency use listing (EUL) inspection conducted from March 14 to 22, and the vaccine maker has indicated its commitment to suspend production of Covaxin for export.

Bharat Biotech did not immediately respond to a request for comment sent outside business hours.

German man got some 90 vaccine shots so he could sell forged passes

On Friday, the vaccine manufacturer said it was slowing production of Covaxin, as demand was dropping along with a fall in infections and wider immunisation coverage in the country.

The WHO said that the company has “committed to comply by addressing the GMP deficiencies and is developing a corrective and preventive action plan, for submission to the Drugs Controller General of India (DCGI) and WHO”.

Post